Vuno Inc. announced that it has entered into a memorandum of understanding with DongKoo Bio&Pharma Co., Ltd. (KOSDAQ:A006620) and received KRW 3,000,000,000 in a round of funding on May 19, 2020. The company is pushing for an initial public offering within 2020.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28,750 KRW | +2.86% | -1.54% | -31.55% |
Mar. 26 | Vuno Inc. announced that it has received KRW 10.4 billion in funding | CI |
Mar. 21 | Vuno Inc. announced that it expects to receive KRW 10.4 billion in funding | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.55% | 279M | |
+9.56% | 3.18B | |
-6.45% | 3.13B | |
-34.10% | 1.57B | |
-57.28% | 740M | |
-32.91% | 554M | |
-17.24% | 319M | |
-13.91% | 204M | |
-12.44% | 169M | |
-3.23% | 129M |
- Stock Market
- Equities
- A338220 Stock
- News Vuno Inc.
- Vuno Inc. announced that it has received KRW 3 billion in funding from DongKoo Bio&Pharma Co., Ltd.